EFFECT OF LIFIBROL ON PLASMA LIPOPROTEINS

这项研究的具体目的是确定利福平是否会降低 低密度脂蛋白受体缺陷患者的低密度脂蛋白水平。 这些患者对诱导合成的药物治疗具有抵抗力。 低密度脂蛋白受体，如3-羟色胺的竞争性抑制物 羟基-3甲基戊二酰辅酶A(HMGCoA)还原酶。利非罗尔有 已被证明能抑制胆固醇的生物合成，买不起有竞争力的产品 HMGCoA还原酶抑制剂。虽然这一特定的机制 Lifil的作用尚不清楚，该药物已显示出降低 胆固醇以剂量依赖的方式。最佳剂量可降低低密度脂蛋白 大约40%。降胆固醇的幅度类似于 HMGCoA还原酶抑制剂。

The specific aim of this study is to determine whether lifibrol lowers LDL cholesterol levels in patients who are deficient in LDL-receptors. These patients are resistant to drug therapies that induce synthesis of LDL-receptors such as competitive inhibitors of 3- hydroxy-3methylglutaryl coenzyme A (HMGCoA) reductase. Lifibrol has been shown to inhibit cholesterol biosynthesis buy not as a competitive inhibitor of HMGCoA reductase. Although the specific mechanism of action of lifibrol is not known, the drug has been shown to lower cholesterol in a dose-dependent manner. Optimum doses lower LDL by about 40%. The magnitude of cholesterol-lowering is similar to the HMGCoA reductase inhibitors.